tach 101

Zavondemstat (QC8222) is an orally active, selective inhibitor of the histone lysine demethylase 4 (KDM4) family, with an IC₅₀ of ≤ 0.08 μM against human KDM4A–D and a K₊₀ of 0.52 μM against human KDM4C. Zavondemstat activates tumor suppressor genes, induces apoptosis, causes S-phase cell cycle arrest, and inhibits cancer cell proliferation. In in vivo studies, Zavondemstat inhibits tumor growth and induces tumor regression. Zavondemstat can be used in cancer research.

Zavondemstat (L-lysine) (QC8222; TACH 101) is an inhibitor of the histone lysine demethylase 4D (KDM4D) with antitumor properties.

Zavondemstat sodium (Compound 15) serves as an intermediate in the synthesis of Compound 8, which functions as a histone demethylase inhibitor. Compound 8 is applicable in cancer research.